Trials / Completed
CompletedNCT05547906
Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors
An Open-label, Dose-escalation, Dose-expansion, Phase 1 Study to Evaluate the Tolerability, Safety, Pharmacokinetics/Pharmacodynamics, and Antitumor Effect of ASCA101 in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- MetaFines · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, open-label, dose escalation Phase 1 study. The purpose of this study is to evaluate the following objectives in patients with advanced solid tumors after failure of standard of care.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASCA101 | IV infusion Twice a Week, 8 times per each Cycle |
Timeline
- Start date
- 2021-11-08
- Primary completion
- 2024-02-29
- Completion
- 2024-02-29
- First posted
- 2022-09-21
- Last updated
- 2024-03-13
Locations
2 sites across 2 countries: United States, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05547906. Inclusion in this directory is not an endorsement.